论文部分内容阅读
目的 探讨晚期胃癌应用DMF方案及EAM方案的疗效与毒副作用。方法 1995年 1月至 1998年 12月用DMF方案 (DDP、MMC、5 Fu)与FAM方案 (5 Fu、ADM、MMC)治疗晚期胃癌 56例。结果 DMF方案治疗 2 8例 ,有效率 (CR +PR) 53 6 %。FAM方案治疗 2 8例 ,有效率 (CR +PR)57 1%。两组疗效经x2 统计学处理无显著差异性。两组毒副反应均有消化道反应和骨髓抑制 ,DMF组的消化道反应较FAM组重 ,而骨髓抑制较FAM组轻。FAM组有明显的脱发 ,2例出现心脏毒性反应。DMF组无脱发及心脏毒性反应 ,DDP的肾毒性经水化后得以预防。结论 DMF组疗效与FAM组相似 ,毒副作用经对症处理均可耐受 ,无脱发及心脏毒性 ,价格较低。
Objective To investigate the efficacy and side effects of DMF and EAM regimen in advanced gastric cancer. Methods From January 1995 to December 1998, 56 patients with advanced gastric cancer were treated with DMF (DDP, MMC, 5 Fu) and FAM (5 Fu, ADM, MMC). Results The DMF regimen was used to treat 28 patients with an effective rate (CR + PR) of 536%. The FAM regimen treated 28 patients with an effective rate (CR +PR) of 57 1%. There was no significant difference in the efficacy of x2 between the two groups. There were gastrointestinal reactions and myelosuppression in both groups. The gastrointestinal response of the DMF group was heavier than that of the FAM group, and myelosuppression was lighter than that of the FAM group. There was significant hair loss in the FAM group and cardiotoxicity in 2 cases. There was no hair loss and cardiotoxicity reaction in the DMF group, and the renal toxicity of DDP was prevented after hydration. Conclusion The efficacy of the DMF group is similar to that of the FAM group. The toxic and side effects can be tolerated with symptomatic treatment, no hair loss and cardiotoxicity, and the price is low.